MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 348-361

  Gits, Caroline M M ^a   Van Kuijk, Patricia F ^a   Jonkers, Moniek B E ^a   Boersma, Antonius W M ^a   Smid, Marcel ^a   Van Ijcken, Wilfred F ^b   Coindre, Jean Michel ^c   Chibon, Fréderic ^c   Verhoef, Cornelis ^a   Mathijssen, Ron H J ^a   Den Bakker, Michael A ^b   Verweij, Jaap ^a   Sleijfer, Stefan ^a   Wiemer, Erik A C ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c INSTITUT BERGONIÉ   (France)

Author keywords

liposarcoma; microRNA; miR 145; miR 451; tumor suppressors

Indexed keywords

MICRORNA; MICRORNA 143; MICRORNA 144; MICRORNA 145; MICRORNA 451; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOSARCOMA; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; TUMOR CELL LINE; UPREGULATION;

LIPOSARCOMA; MICRORNA; MIR-145; MIR-451; TUMOR SUPPRESSORS;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CLUSTER ANALYSIS; FEMALE; FLOW CYTOMETRY; GENES, TUMOR SUPPRESSOR; HUMANS; LIPOSARCOMA; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTOME; TRANSFECTION;

EID: 84900032521     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28694     Document Type: Article

References (50)

1. Ducimetiere F, Lurkin A, Ranchere-Vince D, et al. Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhone-Alpes region. Bull Cancer 2010; 97: 629-41.
2. Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer 2006; 119: 2922-30.
3. Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F, eds. WHO classification of tumours of soft tissue and boneed. Lyon: IARC, 2013.
4. Pedeutour F, Suijkerbuijk RF, Van Gaal J, et al. Chromosome 12 origin in rings and giant markers in well-differentiated liposarcoma. Cancer Genet Cytogenet 1993; 66: 133-4.
5. Dei Tos AP, Doglioni C, Piccinin S, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 2000; 190: 531-6.
6. Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 2006; 244: 381-91.
7. Singer S, Antonescu CR, Riedel E, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003; 238: 358-70; discussion 70-1.
8. Alvegard TA, Berg NO,. Histopathology peer review of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol 1989; 7: 1845-51.
9. Lehnhardt M, Daigeler A, Hauser J, et al. The value of expert second opinion in diagnosis of soft tissue sarcomas. J Surg Oncol 2008; 97: 40-3.
10. Ray-Coquard I, Montesco MC, Coindre JM, et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol 2012; 23: 2442-9.
11. de Vreeze RS, de Jong D, Nederlof PM, et al. Added value of molecular biological analysis in diagnosis and clinical management of liposarcoma: a 30-year single-institution experience. Ann Surg Oncol 2010; 17: 686-93.
12. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 2007; 31: 1476-89.
13. Fletcher CD, Akerman M, Dal Cin P, et al. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the chromosomes and morphology (CHAMP) collaborative study group. Am J Pathol 1996; 148: 623-30.
14. Bassett MD, Schuetze SM, Disteche C, et al. Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognostication. Cancer 2005; 103: 409-16.
15. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005; 29: 1340-7.
16. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007; 67: 6626-36.
17. Gobble RM, Qin LX, Brill ER, et al. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res 2011; 71: 2697-705.
18. Spitzer JI, Ugras S, Runge S, et al. mRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma. Genes Chromosomes Cancer 2011; 50: 338-47.
19. Brill E, Gobble R, Angeles C, et al. ZIC1 overexpression is oncogenic in liposarcoma. Cancer Res 2010; 70: 6891-901.
20. Munker R, Calin GA,. MicroRNA profiling in cancer. Clin Sci (Lond) 2011; 121: 141-58.
21. Pritchard CC, Cheng HH, Tewari M,. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012; 13: 358-69.
22. Chen CZ,. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353: 1768-71.
23. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
24. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
25. Barbarotto E, Schmittgen TD, Calin GA,. MicroRNAs and cancer: profile, profile, profile. Int J Cancer 2008; 122: 969-77.
26. Gougelet A, Perez J, Pissaloux D, et al. miRNA profiling: how to bypass the current difficulties in the diagnosis and treatment of sarcomas. Sarcoma 2011; 2011: 460650.
27. Subramanian S, Lui WO, Lee CH, et al. MicroRNA expression signature of human sarcomas. Oncogene 2008; 27: 2015-26.
28. Renner M, Czwan E, Hartmann W, et al. MicroRNA profiling of primary high-grade soft tissue sarcomas. Genes Chromosomes Cancer 2012; 51: 982-96.
29. Borjigin N, Ohno S, Wu W, et al. TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma. Biochem Biophys Res Commun 2012; 427: 355-60.
30. Zhang P, Bill K, Liu J, et al. MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer Res 2012; 72: 1751-62.
31. Bianchini L, Saada E, Gjernes E, et al. Let-7 microRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: analysis of 56 lipomas and liposarcomas with molecular cytogenetic data. Genes Chromosomes Cancer 2011; 50: 442-55.
32. Tap WD, Eilber FC, Ginther C, et al. Evaluation of well-differentiated/ de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer 2011; 50: 95-112.
33. Ugras S, Brill E, Jacobsen A, et al. Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. Cancer Res 2011; 71: 5659-69.
34. Taylor BS, DeCarolis PL, Angeles CV, et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov 2011; 1: 587-97.
35. Hisaoka M, Matsuyama A, Nakamoto M,. Aberrant calreticulin expression is involved in the dedifferentiation of dedifferentiated liposarcoma. Am J Pathol 2012; 180: 2076-83.
36. Pothof J, Verkaik NS, van IJcken W, et al. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J 2009; 28: 2090-9.
37. Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005; 41: 2853-60.
38. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
39. Mendell JT,. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008; 133: 217-22.
40. Italiano A, Cardot N, Dupre F, et al. Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the "missing link" between lipomas and liposarcomas? Int J Cancer 2007; 121: 308-15.
41. Mentzel T,. Biological continuum of benign, atypical, and malignant mesenchymal neoplasms-does it exist? J Pathol 2000; 190: 523-5.
42. Fritz B, Schubert F, Wrobel G, et al. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 2002; 62: 2993-8.
43. Suh SO, Chen Y, Zaman MS, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 2011; 32: 772-8.
44. Dou L, Zheng D, Li J, et al. Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression. Oncogene 2012; 31: 507-17.
45. Sachdeva M, Mo YY,. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2010; 2: 170-80.
46. Bandres E, Bitarte N, Arias F, et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 2009; 15: 2281-90.
47. Xu Q, Liu LZ, Qian X, et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012; 40: 761-74.
48. Wang R, Wang ZX, Yang JS, et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011; 30: 2644-58.
49. Thorsen SB, Obad S, Jensen NF, et al. The therapeutic potential of microRNAs in cancer. Cancer J 2012; 18: 275-84.
50. Kitade Y, Akao Y,. MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J Pharmacol Sci 2010; 114: 276-80.